Atrial Fibrillation vs Stroke — Clinical Trial Comparison
Atrial Fibrillation
Irregular heart rhythm increasing clot risk
VS
Stroke
Brain blood supply blocked or bleeding
Atrial fibrillation (AF) and stroke are deeply connected — AF causes roughly 1 in 5 ischaemic strokes. However, their clinical trial landscapes are distinct. AF trials focus on rhythm control, anticoagulation, and catheter ablation, while stroke trials target acute intervention, rehabilitation, and secondary prevention.
Key Differences at a Glance
| Feature | Atrial Fibrillation | Stroke |
|---|---|---|
| Nature | Chronic heart rhythm disorder | Acute neurological emergency (ischaemic or haemorrhagic) |
| UK prevalence | ~1.5 million diagnosed | ~100,000 strokes per year (~1.3 million survivors) |
| Primary risk | 5× increased stroke risk, heart failure | Death, permanent disability, recurrent stroke |
| Key diagnostic tools | ECG, Holter monitor, echocardiogram | CT/MRI brain, CT angiography, NIHSS score |
| Connection | AF is a leading cause of ischaemic stroke | ~20% of strokes are cardioembolic from AF |
| Treatment urgency | Usually chronic management (rate/rhythm control) | Hyper-acute: thrombolysis within 4.5 hours, thrombectomy within 6 hours |
Clinical Trial Availability
| Trial Aspect | Atrial Fibrillation | Stroke |
|---|---|---|
| UK trials actively recruiting | 40–60 studies | 60–90 studies |
| Most common trial phase | Phase 2–3 (device and drug) | Phase 2–3 (acute), Phase 3–4 (rehab) |
| Top interventions tested | Catheter ablation techniques, LAA closure devices, novel anticoagulants, mapping technology | Thrombectomy devices, neuroprotection, stem cell therapy, brain stimulation for recovery |
| Device trials | Major category (ablation catheters, LAA occluders) | Significant (clot retrieval devices, brain stimulators) |
| Prevention trials | Anticoagulation optimisation, ablation for stroke prevention | Secondary prevention, lifestyle, blood pressure management |
| Rehabilitation trials | Limited (fatigue, QoL) | Major category (physical, cognitive, speech therapy) |
Exciting Emerging Treatments
Atrial Fibrillation Trials
- Pulsed field ablation (PFA) — non-thermal ablation targeting heart tissue without collateral damage
- Next-generation LAA closure devices — less invasive alternatives to long-term anticoagulation
- AI-guided ablation mapping — machine learning to identify optimal ablation targets
- Factor XIa inhibitors — novel anticoagulants with potentially lower bleeding risk
- Wearable AF detection — smartwatch-based screening and early intervention trials
- Hybrid epicardial-endocardial ablation — for persistent AF resistant to standard ablation
Stroke Trials
- Extended thrombectomy window — trials pushing beyond 6 hours with advanced imaging selection
- Stem cell therapy for recovery — regenerative approaches to repair damaged brain tissue
- Brain-computer interfaces — devices to restore movement in paralysed limbs
- Neuroprotective agents — drugs to limit brain damage during acute stroke
- Virtual reality rehabilitation — immersive therapy for motor and cognitive recovery
- Remote ischaemic conditioning — simple, non-invasive neuroprotection technique
💡 Had a stroke from AF? You may qualify for both types of trials
Cardioembolic stroke survivors with AF can access both stroke recovery trials and AF management trials. Secondary prevention studies (anticoagulation optimisation, LAA closure) are particularly relevant. Your stroke physician and cardiologist can coordinate to find the right trial for you.
Eligibility Differences
Atrial Fibrillation Trial Criteria
- AF type specified (paroxysmal, persistent, permanent) — trials often target specific types
- CHA₂DS₂-VASc score determines stroke risk category (relevant for anticoagulation trials)
- Prior ablation may exclude from first-line ablation trials but qualify for redo/refractory studies
- Anticoagulation status matters — some trials require stable anticoagulation, others test alternatives
- Left atrial size and duration of AF affect ablation trial eligibility
Stroke Trial Criteria
- Stroke type critical — ischaemic vs haemorrhagic trials are entirely separate
- Time from onset is paramount — acute trials require presentation within hours
- NIHSS score determines severity category (mild, moderate, severe)
- Rehabilitation trials may require stability (days to weeks post-stroke)
- Imaging findings (infarct size, location, penumbra) determine many acute trial eligibility criteria
❤️🩹 AF Trials
Find actively recruiting atrial fibrillation clinical trials across the UK
View AF Trials